Endogenex, in partnership with Mayo Clinic, aims to revolutionize treatment options for individuals with type 2 diabetes (T2D). Endogenex’s innovations focus on resetting the body’s metabolic signaling system by harnessing its natural regenerative capabilities to improve metabolic function. Through the development of the Endogenex System and the novel application of precise, controlled, non-thermal pulsed electric fields, Endogenex is establishing a new era in treatment options for people living with T2D, helping patients regain control of their blood glucose levels and slow disease progression. Endogenex is a privately held, clinical-stage company based in Minneapolis, MN.
| Website | https://www.endogenex.com/ |
| Employees | 29 (20 on RocketReach) |
| Founded | 2017 |
| Address | 13755 1st Ave N Suite 100, Plymouth, Minnesota 55441, US |
| Industry | Medical Equipment Manufacturing |
| Keywords | Type 2 Diabetes Treatment, Diabetes Management Programs, Regenerative Medicine, Diabetes Research, Cellular Regeneration, Diabetes Reversal, Innovative Medical Technology, Health And Wellness Programs, Diabetes Prevention, Personalized Diabetes Care |
| Competitors | Roche, Novartis, AbbVie, Merck & Co., Inc., Pfizer, Bristol Myers Squibb, Genentech, Amgen, Gilead Sciences, Lilly India +42 more (view full list) |
Looking for a particular Endogenex employee's phone or email?
Stacey Pugh is the CEO of Endogenex.
20 people are employed at Endogenex.
Endogenex is based in Plymouth, Minnesota.